New Path to Treat Advanced Triple-Negative Breast Cancer

A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer, one of the most difficult disease sub-types to treat.